Thursday, February 11, 2016


AstraZeneca CEO David Brennan to depart

AstraZeneca chief executive officer David Brennan said Thursday he would retire June 1 in the wake of another difficult quarter for the pharmaceutical manufacturer.

AstraZeneca CEO David Brennan to depart


AstraZeneca chief executive officer David Brennan said Thursday he would retire June 1 in the wake of another difficult quarter for the pharmaceutical manufacturer.

AstraZeneca is based in the United Kingdom and released disappointing first-quarter first-quarter earnings along with Brennan's news before the markets opened in London.

AstraZeneca's U.S. headquarters is in Wilmington and it has a plant in Newark, Del.

The company has struggled lately as it tried to replace revenue from some of its blockbuster drugs that were facing generic competition because their patents are expiring. AstraZeneca's best-selling drugs are Crestor (cardiovascular), Seroquel (anti-psychotic) and Nexium (gastrointestinal).

More coverage
AstraZeneca chief under pressure

Total revenue fell 11 percent in the first quarter and the operating profit dropped 37 percent.

The company has had several rounds of layoffs, including to staff in Delaware.

“The pharmaceutical sector is experiencing pressures none of which I’ve witnessed in my 36 years in the industry," Brennan said during a Thursday conference call. "I remain very confident that AstraZeneca has the capabilities, courage and determination to be successful into the future. If we maintain our focus on meeting the needs of patients and trying to solve unmet patient needs, we can continue to deliver attractive and sustained returns for our shareholders.

“The time for reflection on what has been a long and rewarding career with AstraZeneca will have to wait until I hand over responsibilities. For now, my attention remains and will continue to remain 100 percent focused on delivering our strategy. But I do want to say that I am proud of what we have achieved in my time as chief executive."

AstraZeneca also said that Leif Johansson will succeed Louis Schweitzer as non-executive chairman of the board on June 1 – three months earlier than previously announced – and will become chairman of the nomination and governance committee after Thursday's annual meeting. That means Johansson will guide the selection for Brennan’s successor.

Chief financial officer Simon Lowth will act as interim CEO after Brennan departs and until his replacement is named. Julie Brown, a vice president of group finance, will become interim CFO.

Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Staff Writer
Also on
letter icon Newsletter